Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 142


Paliperidone Palmitate Once-Monthly Injectable Treatment for Acute Exacerbations of Schizoaffective Disorder.

Fu DJ, Turkoz I, Simonson RB, Walling D, Schooler N, Lindenmayer JP, Canuso C, Alphs L.

J Clin Psychopharmacol. 2016 Aug;36(4):372-6. doi: 10.1097/JCP.0000000000000535.


Paliperidone palmitate once-monthly maintains improvement in functioning domains of the Personal and Social Performance scale compared with placebo in subjects with schizoaffective disorder.

Fu DJ, Turkoz I, Walling D, Lindenmayer JP, Schooler NR, Alphs L.

Schizophr Res. 2018 Feb;192:185-193. doi: 10.1016/j.schres.2017.04.004. Epub 2017 Apr 26.


Paliperidone palmitate once-monthly reduces risk of relapse of psychotic, depressive, and manic symptoms and maintains functioning in a double-blind, randomized study of schizoaffective disorder.

Fu DJ, Turkoz I, Simonson RB, Walling DP, Schooler NR, Lindenmayer JP, Canuso CM, Alphs L.

J Clin Psychiatry. 2015 Mar;76(3):253-62. doi: 10.4088/JCP.14m09416.


Estimated medical cost reductions for paliperidone palmitate vs placebo in a randomized, double-blind relapse-prevention trial of patients with schizoaffective disorder.

Joshi K, Lin J, Lingohr-Smith M, Fu DJ.

J Med Econ. 2015;18(8):629-36. doi: 10.3111/13696998.2015.1033424. Epub 2015 Apr 22.


Rapid onset of treatment effects on psychosis, depression, and mania in patients with acute exacerbation of schizoaffective disorder following treatment with oral extended-release paliperidone.

Fu DJ, Turkoz I, Bossie CA, Patel H, Alphs L.

J Affect Disord. 2016 Mar 15;193:381-90. doi: 10.1016/j.jad.2015.12.060. Epub 2015 Dec 31.


Paliperidone for the treatment of schizoaffective disorder.

Alphs L, Fu DJ, Turkoz I.

Expert Opin Pharmacother. 2016;17(6):871-83. doi: 10.1517/14656566.2016.1161029. Epub 2016 Mar 24. Review.


An open-treatment six-week study of the clinical effectiveness of Paliperidone Palmitate in schizophrenia: data from acute units in Spain (SHADOW study).

Parellada E, Bioque M, Serrano M, Herrera B, García Dorado M; SHADOW Study Group.

Int J Psychiatry Clin Pract. 2018 Sep;22(3):191-199. doi: 10.1080/13651501.2017.1404112. Epub 2017 Nov 21.


Paliperidone extended-release in schizoaffective disorder: a randomized, controlled study comparing a flexible dose with placebo in patients treated with and without antidepressants and/or mood stabilizers.

Canuso CM, Schooler N, Carothers J, Turkoz I, Kosik-Gonzalez C, Bossie CA, Walling D, Lindenmayer JP.

J Clin Psychopharmacol. 2010 Oct;30(5):487-95. doi: 10.1097/JCP.0b013e3181eeb600.


Paliperidone Palmitate Once-Monthly Treatment in Recent Onset and Chronic Illness Patients With Schizoaffective Disorder.

Bossie CA, Turkoz I, Alphs L, Mahalchick L, Fu DJ.

J Nerv Ment Dis. 2017 Apr;205(4):324-328. doi: 10.1097/NMD.0000000000000646.


Efficacy and safety of once-monthly paliperidone palmitate long-acting injection in an elderly patient with schizophrenia.

Rama Raj P, Lewis M, Macfarlane S.

BMJ Case Rep. 2015 Aug 26;2015. pii: bcr2015212149. doi: 10.1136/bcr-2015-212149.


Efficacy and Safety of Paliperidone Palmitate 3-Month Formulation for Patients with Schizophrenia: A Randomized, Multicenter, Double-Blind, Noninferiority Study.

Savitz AJ, Xu H, Gopal S, Nuamah I, Ravenstijn P, Janik A, Schotte A, Hough D, Fleischhacker WW.

Int J Neuropsychopharmacol. 2016 Jul 5;19(7). pii: pyw018. doi: 10.1093/ijnp/pyw018. Print 2016 Jul.


Benefit-risk assessment of paliperidone oral extended-release tablet versus monthly injectable for maintenance treatment of schizophrenia.

Levitan B, Markowitz M, Turkoz I, Fu DJ, Gopal S, Alphs L.

Int Clin Psychopharmacol. 2016 Nov;31(6):315-22. doi: 10.1097/YIC.0000000000000141.


Paliperidone Palmitate 3-Monthly Versus 1-Monthly Injectable in Patients With Schizophrenia With or Without Prior Exposure to Oral Risperidone or Paliperidone: A Post Hoc, Subgroup Analysis.

Mathews M, Pei H, Savitz A, Nuamah I, Hough D, Alphs L, Gopal S.

Clin Drug Investig. 2018 Aug;38(8):695-702. doi: 10.1007/s40261-018-0647-z.


Pharmacokinetics, safety, and tolerability of paliperidone palmitate 3-month formulation in patients with schizophrenia: A phase-1, single-dose, randomized, open-label study.

Ravenstijn P, Remmerie B, Savitz A, Samtani MN, Nuamah I, Chang CT, De Meulder M, Hough D, Gopal S.

J Clin Pharmacol. 2016 Mar;56(3):330-9. doi: 10.1002/jcph.597. Epub 2015 Oct 5.


Switching from oral atypical antipsychotic monotherapy to paliperidone palmitate once-monthly in non-acute patients with schizophrenia: A prospective, open-label, interventional study.

Schreiner A, Caspi A, Bergmans P, Cherubin P, Keim S, Lara E, Pinchuk I, Schuepbach D, Suleman S, Hargarter L.

Psychopharmacology (Berl). 2017 Jan;234(1):3-13. doi: 10.1007/s00213-016-4445-0. Epub 2016 Nov 5.


Paliperidone palmitate in non-acute patients with schizophrenia previously unsuccessfully treated with risperidone long-acting therapy or frequently used conventional depot antipsychotics.

Schreiner A, Bergmans P, Cherubin P, Keim S, Llorca PM, Cosar B, Petralia A, Corrivetti G, Hargarter L.

J Psychopharmacol. 2015 Aug;29(8):910-22. doi: 10.1177/0269881115586284. Epub 2015 May 21.


Efficacy and safety of risperidone in the treatment of schizoaffective disorder: initial results from a large, multicenter surveillance study. Group for the Study of Risperidone in Affective Disorders (GSRAD).

Vieta E, Herraiz M, Fernández A, Gastó C, Benabarre A, Colom F, Martínez-Arán A, Reinares M.

J Clin Psychiatry. 2001 Aug;62(8):623-30.


Intramuscular long-acting paliperidone palmitate in acute patients with schizophrenia unsuccessfully treated with oral antipsychotics.

Hargarter L, Cherubin P, Bergmans P, Keim S, Rancans E, Bez Y, Parellada E, Carpiniello B, Vidailhet P, Schreiner A.

Prog Neuropsychopharmacol Biol Psychiatry. 2015 Apr 3;58:1-7. doi: 10.1016/j.pnpbp.2014.11.006. Epub 2014 Nov 15.


Adjunctive long-acting risperidone in patients with bipolar disorder who relapse frequently and have active mood symptoms.

Macfadden W, Adler CM, Turkoz I, Haskins JT, Turner N, Alphs L.

BMC Psychiatry. 2011 Oct 28;11:171. doi: 10.1186/1471-244X-11-171.


Cost-Effectiveness of Long-Acting Injectable Paliperidone Palmitate Versus Haloperidol Decanoate in Maintenance Treatment of Schizophrenia.

Rosenheck RA, Leslie DL, Sint KJ, Lin H, Li Y, McEvoy JP, Byerly MJ, Hamer RM, Swartz MS, Stroup TS.

Psychiatr Serv. 2016 Oct 1;67(10):1124-1130. Epub 2016 Jun 1.

Supplemental Content

Support Center